ALGS (Aligos Therapeutics) OCF Yield %: -206.81 (As of Jul. 11, 2026)


ALGS Aligos Therapeutics Inc ALGS
37 GF Score
Price $6.63
GF Value $2.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics OCF Yield %?

Aligos Therapeutics ALGS -2.22% 37 OCF Yield % is -206.81 as of Jul. 11, 2026. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Aligos Therapeutics ranks worse than 95.46% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Aligos Therapeutics's Trailing 12-Month Cash Flow from Operations is $-84.72 Mil, and Market Cap is $41.03 Mil. Therefore, Aligos Therapeutics's OCF Yield % for today is -206.81%.

The historical rank and industry rank for Aligos Therapeutics's OCF Yield % or its related term are showing as below:

ALGS' s OCF Yield % Range Over the Past 10 Years
Min: -289.82   Med: -116.7   Max: -6.66
Current: -206.81


During the past 8 years, the highest OCF Yield % of Aligos Therapeutics was -6.66%. The lowest was -289.82%. And the median was -116.70%.

ALGS's OCF Yield % is ranked worse than
95.46% of 1409 companies
in the Biotechnology industry
Industry Median: -8.05 vs ALGS: -206.81

Aligos Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Aligos Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Aligos Therapeutics OCF Yield % Related Terms


Aligos Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics OCF Yield % Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial -22.82 -194.09 -158.42 -52.45 -143.29

Aligos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -165.78 -139.84 -161.47 -151.06 -201.21

ALGS vs SNTI, NTRB, CRVO: OCF Yield % Comparison

For the Biotechnology subindustry, Aligos Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aligos Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Aligos Therapeutics's OCF Yield % falls into.


ALGS
37GF Score
Aligos Therapeutics Inc ALGS
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aligos Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Aligos Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-82.503 / 57.57896
=-143.29%

Aligos Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-23.128 * 4 / 45.97684
=-201.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -206.81 mean?
Aligos Therapeutics (ALGS) has a OCF Yield % of -206.81 as of Jul. 11, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Aligos Therapeutics and its competitors. According to the industry distribution chart, Aligos Therapeutics ranks #1345 out of 1409 companies in the Biotechnology industry, placing it in the top 95.5%.
Is Aligos Therapeutics' OCF Yield % too high?
Aligos Therapeutics' current OCF Yield % is -206.81. Based on the distribution chart, Aligos Therapeutics ranks #1345 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' OCF Yield % compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #1345 out of 1409 companies for OCF Yield %. This places Aligos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current OCF Yield % is -206.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current OCF Yield % is -206.81. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current OCF Yield % is -206.81 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for ALGS:

  • OCF Yield %: -206.81
  • GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score

Get the complete analysis for ALGS

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.63
Price
$2.78
GF Value